These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 16376858

  • 1. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.
    Qiu W, Zhou B, Darwish D, Shao J, Yen Y.
    Biochem Biophys Res Commun; 2006 Feb 10; 340(2):428-34. PubMed ID: 16376858
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.
    Shao J, Zhou B, Zhu L, Qiu W, Yuan YC, Xi B, Yen Y.
    Cancer Res; 2004 Jan 01; 64(1):1-6. PubMed ID: 14729598
    [Abstract] [Full Text] [Related]

  • 5. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
    Shao J, Zhou B, Zhu L, Bilio AJ, Su L, Yuan YC, Ren S, Lien EJ, Shih J, Yen Y.
    Biochem Pharmacol; 2005 Feb 15; 69(4):627-34. PubMed ID: 15670581
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
    Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H, Cheng YW.
    Anticancer Res; 2011 Oct 15; 31(10):3475-81. PubMed ID: 21965764
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
    Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, Shih J, Yen Y.
    Mol Cancer Ther; 2006 Mar 15; 5(3):586-92. PubMed ID: 16546972
    [Abstract] [Full Text] [Related]

  • 10. Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.
    Zhou B, Su L, Yuan YC, Un F, Wang N, Patel M, Xi B, Hu S, Yen Y.
    Mol Cancer Ther; 2010 Jun 15; 9(6):1669-79. PubMed ID: 20484015
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
    Krishnan K, Prathiba K, Jayaprakash V, Basu A, Mishra N, Zhou B, Hu S, Yen Y.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6248-50. PubMed ID: 18976907
    [Abstract] [Full Text] [Related]

  • 12. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
    Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W, Yen Y.
    Clin Cancer Res; 2006 Nov 01; 12(21):6337-44. PubMed ID: 17085643
    [Abstract] [Full Text] [Related]

  • 13. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
    Xie M, Yen Y, Owonikoko TK, Ramalingam SS, Khuri FR, Curran WJ, Doetsch PW, Deng X.
    Cancer Res; 2014 Jan 01; 74(1):212-23. PubMed ID: 24197132
    [Abstract] [Full Text] [Related]

  • 14. Structurally dependent redox property of ribonucleotide reductase subunit p53R2.
    Xue L, Zhou B, Liu X, Wang T, Shih J, Qi C, Heung Y, Yen Y.
    Cancer Res; 2006 Feb 15; 66(4):1900-5. PubMed ID: 16488986
    [Abstract] [Full Text] [Related]

  • 15. 2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase .
    Smith P, Zhou B, Ho N, Yuan YC, Su L, Tsai SC, Yen Y.
    Biochemistry; 2009 Nov 24; 48(46):11134-41. PubMed ID: 19728742
    [Abstract] [Full Text] [Related]

  • 16. The structural basis for the allosteric regulation of ribonucleotide reductase.
    Ahmad MF, Dealwis CG.
    Prog Mol Biol Transl Sci; 2013 Nov 24; 117():389-410. PubMed ID: 23663976
    [Abstract] [Full Text] [Related]

  • 17. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
    Ahmad MF, Alam I, Huff SE, Pink J, Flanagan SA, Shewach D, Misko TA, Oleinick NL, Harte WE, Viswanathan R, Harris ME, Dealwis CG.
    Proc Natl Acad Sci U S A; 2017 Aug 01; 114(31):8241-8246. PubMed ID: 28716944
    [Abstract] [Full Text] [Related]

  • 18. Protein properties of the subunits of ribonucleotide reductase and the specificity of the allosteric site(s).
    Cory JG, Sato A, Brown NC.
    Adv Enzyme Regul; 1986 Aug 01; 25():3-19. PubMed ID: 3544706
    [Abstract] [Full Text] [Related]

  • 19. A quantitative model for allosteric control of purine reduction by murine ribonucleotide reductase.
    Scott CP, Kashlan OB, Lear JD, Cooperman BS.
    Biochemistry; 2001 Feb 13; 40(6):1651-61. PubMed ID: 11327824
    [Abstract] [Full Text] [Related]

  • 20. Nucleoside Analogue Triphosphates Allosterically Regulate Human Ribonucleotide Reductase and Identify Chemical Determinants That Drive Substrate Specificity.
    Knappenberger AJ, Ahmad MF, Viswanathan R, Dealwis CG, Harris ME.
    Biochemistry; 2016 Oct 18; 55(41):5884-5896. PubMed ID: 27634056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.